These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23249976)

  • 1. Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197.
    Caro-Aguilar I; Ottinger E; Hepler RW; Nahas DD; Wu C; Good MF; Batzloff M; Joyce JG; Heinrichs JH; Skinner JM
    Hum Vaccin Immunother; 2013 Mar; 9(3):488-96. PubMed ID: 23249976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: progress towards Phase I trial.
    Pandey M; Powell J; Calcutt A; Zaman M; Phillips ZN; Ho MF; Batzloff MR; Good MF
    Sci Rep; 2017 Oct; 7(1):13786. PubMed ID: 29062085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models.
    Rivera-Hernandez T; Pandey M; Henningham A; Cole J; Choudhury B; Cork AJ; Gillen CM; Ghaffar KA; West NP; Silvestri G; Good MF; Moyle PM; Toth I; Nizet V; Batzloff MR; Walker MJ
    mBio; 2016 Jun; 7(3):. PubMed ID: 27302756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.
    Olive C; Schulze K; Sun HK; Ebensen T; Horváth A; Toth I; Guzman CA
    Vaccine; 2007 Feb; 25(10):1789-97. PubMed ID: 17229503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical safety and immunogenicity of Streptococcus pyogenes (Strep A) peptide vaccines.
    Reynolds S; Pandey M; Dooley J; Calcutt A; Batzloff M; Ozberk V; Mills JL; Good M
    Sci Rep; 2021 Jan; 11(1):127. PubMed ID: 33420258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modular virus-like particles for sublingual vaccination against group A streptococcus.
    Seth A; Kong IG; Lee SH; Yang JY; Lee YS; Kim Y; Wibowo N; Middelberg AP; Lua LH; Kweon MN
    Vaccine; 2016 Dec; 34(51):6472-6480. PubMed ID: 27866769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from
    Ozberk V; Reynolds S; Huo Y; Calcutt A; Eskandari S; Dooley J; Mills JL; Rasmussen IS; Dietrich J; Pandey M; Good MF
    mBio; 2021 Feb; 12(1):. PubMed ID: 33622722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope.
    Olive C; Clair T; Yarwood P; Good MF
    Vaccine; 2002 Jun; 20(21-22):2816-25. PubMed ID: 12034109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FbaA- and M protein-based multi-epitope vaccine elicits strong protective immune responses against group A streptococcus in mouse model.
    Ma C; Liu Z; Li W; Qian X; Zhang S; Gao X; Jiang S; Wei L
    Microbes Infect; 2014 May; 16(5):409-18. PubMed ID: 24704476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR/S Mutant Streptococci.
    Pandey M; Mortensen R; Calcutt A; Powell J; Batzloff MR; Dietrich J; Good MF
    J Immunol; 2016 Apr; 196(8):3364-74. PubMed ID: 26969753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbially synthesized modular virus-like particles and capsomeres displaying group A streptococcus hypervariable antigenic determinants.
    Chuan YP; Wibowo N; Connors NK; Wu Y; Hughes FK; Batzloff MR; Lua LH; Middelberg AP
    Biotechnol Bioeng; 2014 Jun; 111(6):1062-70. PubMed ID: 24338691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus.
    Wozniak A; Scioscia N; García PC; Dale JB; Paillavil BA; Legarraga P; Salazar-Echegarai FJ; Bueno SM; Kalergis AM
    Microbiol Immunol; 2018 Jun; 62(6):395-404. PubMed ID: 29704396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate.
    Batzloff MR; Fane A; Gorton D; Pandey M; Rivera-Hernandez T; Calcutt A; Yeung G; Hartas J; Johnson L; Rush CM; McCarthy J; Ketheesan N; Good MF
    Hum Vaccin Immunother; 2016 Dec; 12(12):3089-3096. PubMed ID: 27541593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel live vector group A streptococcal emm type 9 vaccine delivered intranasally protects mice against challenge infection with emm type 9 group A streptococci.
    Wozniak A; García P; Geoffroy EA; Aguirre DB; González SA; Sarno VA; Dale JB; Salazar-Echegarai FJ; Vera A; Bueno SM; Kalergis AM
    Clin Vaccine Immunol; 2014 Sep; 21(9):1343-9. PubMed ID: 25056362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens.
    Olive C; Batzloff M; Horváth A; Clair T; Yarwood P; Toth I; Good MF
    Infect Immun; 2003 May; 71(5):2373-83. PubMed ID: 12704107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sporozoite neutralizing antibodies elicited in mice and rhesus macaques immunized with a Plasmodium falciparum repeat peptide conjugated to meningococcal outer membrane protein complex.
    Przysiecki C; Lucas B; Mitchell R; Carapau D; Wen Z; Xu H; Wang XM; Nahas D; Wu C; Hepler R; Ottinger E; Ter Meulen J; Kaslow D; Shiver J; Nardin E
    Front Cell Infect Microbiol; 2012; 2():146. PubMed ID: 23226683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with a streptococcal multiple-epitope recombinant protein protects mice against invasive group A streptococcal infection.
    Kuo CF; Tsao N; Hsieh IC; Lin YS; Wu JJ; Hung YT
    PLoS One; 2017; 12(3):e0174464. PubMed ID: 28355251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies.
    Olive C; Batzloff MR; Horváth A; Wong A; Clair T; Yarwood P; Toth I; Good MF
    Infect Immun; 2002 May; 70(5):2734-8. PubMed ID: 11953422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide amphiphile micelles self-adjuvant group A streptococcal vaccination.
    Trent A; Ulery BD; Black MJ; Barrett JC; Liang S; Kostenko Y; David NA; Tirrell MV
    AAPS J; 2015 Mar; 17(2):380-8. PubMed ID: 25527256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
    Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
    J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.